Abstract 43P
Background
Hotspot constitutive activating of phosphatidylinositol 3 kinase (PI3K) signaling plays a critical role in metastatic breast cancer (MBC). Our previous studies found that oncogenic hotspot mutations of subunit alpha of PI3K (PIK3CA) within the p110α kinase domain (H1047R and H1047L) leads to cell motility and promotes tumor metastasis in invasive ductal breast carcinomas of Chinese women. This study is aimed to elucidate the mutagenetic, homology modelling and function of hotspot variants p.H1047R and p.H1047L in p110α/ΔNp63α complex.
Methods
Here, an established protocol by integrated molecular dynamics, protein-protein docking with combination principal component analysis assay were employed to examine the onco-activation inhibitory function of p110α/ΔNp63α complex between wild and both p110αH1047Rand p110αH1047Lmutation’s conformational diversity. Then, we were confirmed the possible disruption and inhibitory effect of the p110α/ΔNp63α complex at in vitromodel of MBC.
Results
Partial disruption of interaction between the DNA binding domain of ΔNp63α and kinase domain of p110α were destabilized the conformation of activation loop of p110α/ΔNp63α complex in three helix regions, including H1 (resid 234-236), H2 (resid 245-249) and H3 (resid 348-355). The molecular dynamics finding clearly confirmed that ABD (resid 16-105) and C2 domain (resid 330-487) in p.H1047R mutant and RBD (resid 187-289) and kinase domain (resid 797-1068) in p.H1047L mutant are maxima difference of residue level displacements and fluctuations of p110α/ΔNp63α complex. Notably, oncogenic p.H1047L variant is more treatable and distributed structure more than p.H1047R. In vitro result show that abrogation of oncogenic hotspot mutations p.H1047R and p.H1047L in p110α/ΔNp63α complex significantly induces scattered cell growth, cell migration and invasion in MBC cell lines.
Conclusions
Oncogenic hotspot mutant forms, p110αH1047R and p110αH1047L, by reducing the inhibitory effect of the ΔNp63αon the kinase domain of p110α, contributes to the progressive causatives of MBC, as well as defines a novel symbiotic strategy for understanding complex protein systems in MBC.
Clinical trial identification
Editorial acknowledgement
The authorswould like to express their appreciation to appreciate Southwest Medical Universityfor its financial support. We also wish to thank the oncology of The Affiliated Hospital of Southwest Medical University for their assistance in the work reported here.We also thank the anonymous referee for his/her very helpful comments, which remarkably improved the quality of this research.
Legal entity responsible for the study
The authors.
Funding
Southwest Medical University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
175P - Hypermethylation of the PCDHB15 promoter predicts the prognosis in gastric cancer
Presenter: Yu-ting Lee
Session: Poster display session
Resources:
Abstract
176P - DCLK1 promotes tumour invasion and metastasis through epithelial-mesenchymal transition and the MEK/ERK pathway in esophageal squamous cell carcinoma
Presenter: Jiannan Yao
Session: Poster display session
Resources:
Abstract
177P - Comparison of nab-paclitaxel plus ramcirumab and paclitaxel plus ramcirumab in patients with pretreated metastatic gastric cancer
Presenter: Yosuke Horita
Session: Poster display session
Resources:
Abstract
178P - Chief cell in stomach have stem cell activity and potential to develop gastric cancer
Presenter: Akihiro Yamamura
Session: Poster display session
Resources:
Abstract
179P - Postoperative Adjuvant transarterial chemoembolization versus surgery alone for resected hepatocellular carcinoma: A propensity-score matching study
Presenter: Mingyu Chen
Session: Poster display session
Resources:
Abstract
180P - LHPP inhibit the cell proliferation and EMT via the TGFβ/SMAD3 signaling pathway in iCCA
Presenter: Dan Wang
Session: Poster display session
Resources:
Abstract
181P - The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
Presenter: Andrew Dean
Session: Poster display session
Resources:
Abstract
182P - Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less
Presenter: Adarsh Das
Session: Poster display session
Resources:
Abstract
183P - Epidemiologic profile of gastric cancer in East Azerbaijan, Iran: 2 years population-based cancer registry results
Presenter: Pooneh Jabbaripour
Session: Poster display session
Resources:
Abstract
184P - Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression
Presenter: Jun Ji
Session: Poster display session
Resources:
Abstract